ArticleBJU international2022
Outcomes of salvage radical prostatectomy after initial irreversible electroporation treatment for recurrent prostate cancer.
Article in BJU international, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 15 citations in OpenAlex.
- Clinical and surgical management of recto-urinary fistula after radical prostatectomy: a systematic review on current evidence.Prostate cancer and prostatic diseases · 2026Review
- Focal irreversible electroporation for the treatment of localised prostate cancer: a systematic review.Translational andrology and urology · 2025Review
- Focal therapy using high-intensity focused ultrasound with intraoperative prostate compression for patients with localized prostate cancer: a multi-center prospective study with 7 year experience.Prostate cancer and prostatic diseases · 2025Article
- Salvage treatments after focal therapy for prostate cancer - a comprehensive review.Prostate cancer and prostatic diseases · 2025Review
- The use of focal therapy for the treatment of prostate cancer in Canada Where are we, how did we get here, and where are we going?Canadian Urological Association journal = Journal de l'Association des urologues du Canada · 2025Review
- Personalized Treatment Strategy in "Low-Risk Prostate Cancer Active Surveillance Candidates" Using Irreversible Electroporation: Prospective Evaluation of Feasibility, Morbidity, Functional and Oncological Outcomes.The world journal of men's health · 2024Article
- The Contemporary Role of Salvage Radical Prostatectomy in the Management of Recurrent Prostate Cancer: An Up-to-Date Review.Life (Basel, Switzerland) · 2024Review
- Salvage Radical Prostatectomy for Recurrent Prostate Cancer: A Systematic Review (French ccAFU).Cancers · 2023Review
- Guidelines of guidelines: focal therapy for prostate cancer, is it time for consensus?BJU international · 2023Review
- Irreversible electroporation as a focal therapy for localized prostate cancer: A systematic review.Indian journal of urology : IJU : journal of the Urological Society of IndiaReview
- A Comprehensive Review of the Current State of Robot-assisted Laparoscopic Salvage Prostatectomy.International braz j urol : official journal of the Brazilian Society of UrologyReview
Corrections and comments
- Commented on by
Authors and funding
12 authors at 5 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo evaluate: (i) safety, (ii) feasibility, and medium-term (iii) oncological and (iv) functional outcomes of salvage radical prostatectomy (sRP) for recurrent localised prostate cancer (PCa) following initial focal therapy using irreversible electroporation (IRE). PATIENTS AND
methodsAn international, multicentre and retrospective analysis of prospectively collected data of patients that underwent sRP for recurrent localised PCa after initial primary IRE treatment. Data were reported on (i) surgical complications, (ii) feasibility of sRP reported by surgeons, (iii) time interval between IRE and sRP and pathology results, and (iv) urinary continence, erectile function, and quality of life.
resultsIn four participating centres, a total of 39 patients with a median (interquartile range [IQR]) age 64 (60-67) years were identified. No serious adverse events occurred during or following sRP and surgery was deemed feasible without difficulties. The median (IQR) time to recurrence following IRE was 14.3 (9.1-38.8) months. Pathology results showed localised disease in 21 patients (53.8%) and locally-advanced disease in 18 (46.2%). Positive surgical margins (PSMs) were observed in 10 patients (25.6%), of which six (15.4%) had significant PSMs. A persistent detectable prostate-specific antigen level was found in one case after sRP, caused by metastatic disease. One patient had a biochemical recurrence 6 months after sRP. These two cases, together with a PSM case, required additional therapy after sRP. After a median (IQR) follow-up of 17.7 (11.8-26.4) months, urinary continence and erectile function were preserved in 34 (94.4%) and 18 patients (52.9%), respectively, while quality of life remained stable.
conclusionsSalvage RP is safe and feasible for patients with recurrent localised PCa following initial IRE treatment. The medium-term oncological and functional outcomes are similar to primary RP. Strict patient selection for focal therapy and standardised follow-up is needed as some patients developed high-grade disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.